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Researcher Describes Early Success with
Macrophages in Treating Metastasis
(Editor's Note: Isaiah J. Fidler, DVM, PhD, Chairman, Department of Cell Biology, is the recipient of the 33rd Ernst W. Bertner
Memorial Award, presented for his work with metastatic cancer
at the 1983 Annual Symposium on Fundamental Cancer Research, sponsored by UT MDAH. He has recently come to UT
MDAH from the National Cancer lnstitute's Frederick Cancer
Research Facility in Frederick, Maryland, where he was director
of the Cancer Metastasis and Treatment Laboratory. He presently holds the Olla S. Stribling Chair at UT MDAH. Here he
answers questions about the metastatic process and new methods for its control.)

Is metastasis the major problem In the treatment of cancer
patients?
It is a major problem in the treatment of patients with solid
tumors. The major cause of death from solid tumors can be
attributed to metastasis, not to the primary tumor.
What Is the process of metastasis? How do cells metastasize?
How cells metastasize is now beginning to be clear. In order to
metastasize, cells from the primary tumor must invade the
surrounding tissue. Of those cells, some pass into the circulation,
either through the lymphatic system or small blood vessels. As
they enter the circulation, these tumor cells are exposed to an
enormous number of host factors or host cells, such as lymphocytes, natural-killer cells, monocytes, polymorphonuclear cells,

platelets, antibodies, and hormones, that destroy the majority of
tumor cells. The cells that survive in the circulation bind to small
capillaries in distant organs, like the lung or the brain, invade the
capillary wall, and enter the organ tissue where they begin to
multiply.
My early work involved the investigation of the precise number
of cells that survive to yield a metastasis. We injected mice with
radiolabeled melanoma cells. By monitoring those radioactive
tumor cells, we found that of all the cells that entered the
circulation, less than 0.1 % survived to yield metastasis. Other
results showed that 1 g of tissue of a breast tumor in a rat would
lead to the shedding into the circulation of 2 x 106 cells each
day. And yet metastasis did not occur that frequently.

Can one assume then that a tumor cell's ablllty to metastasize Is governed by chance?
Not necessarily. The estimate that so few tumor cells can
complete the process of metastasis led to the following question:
Can any cell in a tumor survive the steps of metastasis-invasion
into the circulation, survival in the circulation, proper interaction
with the host cells, getting out of the circulation, and growth-or
are tumor cells heterogeneous, unequal, insofar as metastatic
properties are concerned? Do very few cells in a tumor have the
probability of forming metastases?
We have investigated this issue by performing several experiments. In one such experiment, a primary tumor was cultured and
split. One subculture, maintained as a mass culture, was injected
directly into mice and produced a uniform number of metastases
in each mouse. Clonal lines were begun from cells in the other
subculture; each clone when injected into a mouse, produced a
different number of lung metastases, exhibiting low, intermediate,
or high metastatic potential. Other experiments have confirmed
these findings, indicating that some primary tumors are indeed
comprised of cells with diverse metastatic capacities.
How recent Is the theory of tumor heterogeneity for metastatic properties?
The original observation was recorded in 1889 by an English
physician, Paget. Paget examined autopsy reports of 735 women
with breast cancer. He discovered a very peculiar thing: that
breast cancer metastasis occurs with predictability in some
organs but not in others. He then asked whether metastasis
occurs by chance or as a selective event. His conclusion was that
metastasis occurs as a consequence of two forces: "the seed
and the soil." Some tumor cells are better "seeds" than others,
and some organs are better "soils" than others. But it takes the

Isaiah J. Fidler

Continued on page 6

Home Hyperalimentation Promotes Self-Care
To date, 32 cancer patients at UT MDAH have administered
their own intravenous hyperalimentation ( IVH) at home. Before
1981, when the home IVH program was instituted at UT MDAH,
hospitalization was required for all patients receiving this form of
nutritional support.
According to the program's coordinator, David M. Ota, MD,
Department of Surger y, the program was instituted to free
selected patients from the expense and mental stress of hosp i
talization. Many patients hospitalized to receive IVH, for malnutri
tion caused by cancer or by treatment, are ambulatory and well
enough for short-term self-care. For this reason, a team of
specialists, including a physician, nurses, a pharmacist, and a
dietician, developed the program, establishing criteria for patient
selection and procedures for training the patient and a family
member in home IVH care.
Selection criteria were carefully determined so that those
patients most likely to benefit from home IVH would be chosen.
Candidates for the program must require a minimum of 6 weeks
of IVH and be ambulator y, have a stable metabolic course but
inadequate gastrointestinal tract function, have cancer potentially
respons ive to treatment, and have a family member to help with
the patient's home care.
Selected patients are entered into a 10- to 15-hour course to
learn the principles of good nutrit ion, operation and proper care of
the equipment, and methods of monitoring the body's cond ition.
The course covers the nutritional needs of each patient, con
sidering his or her spec ific disease and treatment, and explains
how IVH meets these needs. The patients are taught how to hang
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The portable intravenous
hyperalimentation vest
allows the patient to re
ceive continuous inf u
sion of hyperaliment a
tion without hospitaliza
tion.

the solution bag on the movable IVH stand and adjust the infusion
pump to compensate for too slow or too fast infusion, as well as
the aseptic techniques used when chang ing dressings and
cleaning the entry site of the catheter. Patients requiring continu
ous infusion learn to assemble and adjust equipment in a
portable vest that allows them freedom of movement while
receiving IVH. The patients also learn to monitor the body's
metabolism by checking body weight and temperature daily and
by testing the urine twice a day to measure the presence of
ketones and sugar. These results are then recorded in the home
IVH manual, which serves as a text for the training course. Upon
completion of the course, patients are given an exit interview by
home IVH team members to confirm their capability of self-care at
home.
Before the patient returns home, arrangements are made for
delivery of supplies and periodic patient checkup. A private
company is contacted to deliver to the patient's home the
individual nutrient solutions and all equipment, including the
storage refrigerator and sterile dressings and tape. In addition,
the patient's family physician is notified and is requested to send
the results of regular blood tests to UT MDAH. The physician is
also given the patient's IVH solution formula and is sent a copy of
the home IVH manual for reference.
Although the program offers only a temporary life-support
system, it has enabled patients to continue receiving much
needed treatment without the necessity of hospitalization. A total
of 2, 300 hospital days has been saved in the program's first year
alone.
(Physicians desiring additional information or a copy of the
patient teaching manual should write or call David M. Ota, MD,
Department of Surgery, MDAH Box 106, The University of Texas
M. D. Anderson Hospital and Tumor Institute at Houston, 6723
Bertner Avenue, Houston, Texas 77030 , (713) 792-6942.-ED)
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CNS Irradiation of Children Found to
Impair Arithmetic-Related Abilities
by Donna R. Copeland, PhD, Department of Pediatrics; Jack M.
Fletcher, PhD;* Betty Pfefferbaum-Levine, MD, Department of
Pediatrics; Norman Jaffe, MD, Department of Pediatrics; Hubert
L. Ried, MD, Department of Pediatrics; and Moshe H. Maor, MD,
Department of Clinical Radiotherapy

Recent studies have reported abnormalities in the neuropsychologic functioning of children who have received central
nervous system (CNS) treatment for cancer. There have been
reports, for example, that CNS treatment in children may result in
long-term cognitive sequelae, particularly when the treatment
involves radiation. However, the studies to date provide a limited
assessment of this possibility due to small numbers of study
participants, inadequate or no control groups, variability in age of
patients at diagnosis, and limitations in neuropsychologic test
batteries.
Our study, designed to correct these deficiencies, has clarified
issues raised by such investigations concerning the long-term
effects of CNS irradiation and of CNS chemotherapy on children.
We have found that CNS irradiation of children affects visualmotor and motor skills and spatial-processing tasks related to
arithmetic, regardless of age at diagnosis; yet CNS chemotherapy alone does not appear to significantly affect cognitive
functioning in children (Table 1).

Population
The study, conducted between 1980 and 1982, was comprised
of 74 patients; thirty-six were female and 38 were male. The
mean age at evaluation for the total group was 14 years. The
mean age at disease diagnosis was 5.5 years. All patients were
long-term survivors of childhood cancer. Long-term survival was
defined as a disease-free state at least 5 years beyond initial
treatment for cancer or for 5 years beyond the last known disease
activity.
The patients were divided into three groups according to type
of treatment received. Two of these groups were comprised of
survivors of childhood leukemia or lymphoma who had received
required CNS prophylaxis. Group I (24 patients) had had acute
leukemia or poorly or undifferentiated lymphoma, which was
treated with chemotherapy only, including intrathecal (IT) medication; those in group II (25 patients) had had acute lymphocytic
leukemia or acute granulocytic leukemia treated with chemotherapy, including IT medication, and CNS irradiation (approximately 2400 rad over a 16-day period). All patients in groups I
and II had been free of CNS involvement at the time of diagnosis,
except a patient in group II with acute granulocytic leukemia.
Group Ill (25 patients), a control group, was comprised of
patients who had had solid tumors or Hodgkin's disease treated
with surgical excision or chemotherapy or both, and, in some
*Developmental Neuropsychology Section, Texas Research Institute of Mental Sci-

ences
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TABLE 1. Mean Scores on Nonlanguage Tests*
For Groups I, II, and I/It
Test*

FSIQ
VlQ
Arithmetic
PIO
Block Design
Coding
WRAT ..,. Spelling
WRAT - Arithmetic
Beery VMI
Spatial Memory (LTS)
Spatial Memory (CR)
Finger Tapping (DH)
Finger Tapping (NDH)
Trailmaking
Grooved Pegboard (DH)
Grooved Pegboard (NDH)

Mean GrouQ Scores

105.63
105.54
10.79
104.96
10.58
11.17
103.85
96.95
9.17
9.55
10.67
11.00
10.20
9.62
12.71
12.02

II

Ill

91 .16
91.84
7.88
92.36
8.00
7.80
92.18
85.78
6.72
6.25
7.54
8.36
8.47
7.18
8.58
7.79

106.88
103.52
10.36
109.80
11.04
10.76
102.88
94.33
10.09
10.06
10.74
12.18
11.78
9.75
11.96
12.17

*Differences between the test scores of the irradiated and nonirradiated groups were
statistically significant for these tests.
tGroup I - 24 patients, CNS chemotherapy only; group II - 25 patients, CNS
chemotherapy and radiation; group Ill - 25 patients, no CNS treatment.
:µbbreviations are as follows: FSIQ = full-scale IQ; VIQ = verbal IQ; PIO =
performance IQ; WRAT = Wide Range Achievement Test; VMI = Visual-Motor
Integration; LTS = long-term storage; CR = continuous retrieval ; DH = dominant
hand; NOH = nondominant hand.

cases, irradiation to sites other than the CNS. Diagnoses in this
group were: malignant bone tumors (7 patients), neuroblastoma
(5 patients), Wilm's tumor (4 patients), soft tissue tumors (3
patients), other solid tumors (4 patients), and Hodgkin's disease
(2 patients).
Patients in each group were evenly distributed in terms of sex,
ethnicity, and age at diagnosis. Statistical comparisons across
demographic variables revealed significant differences only between groups II and Ill for age at evaluation of CNS impairment;
patients in group Ill were older than those in group II (P<.01)
when tested. Because of this age difference, all dependent
measures in the neuropsychologic test battery were standardized
using age-based norms.

Methods
All patients were administered a battery of neuropsychologic
tests that measure functional skills frequently impaired in children
with neurologic disorders. Tests in this battery were based on a
Continued on page 4
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CNS Irradiation
Continued from page 3
developmental model for testing children and have been applied
to many different patient groups, including children with learning
problems, meningitis, head trauma, and other similar problems.
The functional abilities measured and the specific tests employed are as follows: intellectual functioning: The Wechsler
Intelligence Scale for children and the Wechsler -Adult Intelligence Scale measure verbal IQ (VIQ) , performance IQ (PIO),
and full-scale IQ (FSIQ); visual motor and constructional skills:
the Beery Developmental Test of Visual-Motor Integration and
the Recognition-Discrimination Test measure hand and eye
coordination; tactile-spatial skills: the Tactile Perception Test
measures one's ability to identify shapes by touch; fine motor
skills: finger-tapping and trailmaking tasks from the HalsteadReitan Neuropsychologic Test battery and the Grooved Pegboard Test include such tasks as matching two dots or fitting
pegs into holes; memory and learning: the Verbal Selective
Reminding Test and the Nonverbal Selective Reminding Test
permit separate estimates of storage and retrieval skills; language skills: the Peabody Picture Vocabulary Test, Rapid
Automatized Naming Test, and Word Fluency Test measure a
child's ability to express and receive information ; school achievement: spelling and arithmetic subtests of the Wide Range
Achievement Test and the reading recognition and reading
comprehension subtests from the Peabody Individual Achievement Test measure reading and arithmetic skills.
Thirty-five age-adjusted dependent variables, scores of the
various tests, were divided into nine subsets: FSIQ, VIQ, PIO,
visual-motor skills, motor skills, memory, language, academic
achievement, and tactile-spatial skills. Multivariate analysis of
variance (MANOVA) was used to compare differences among
the three treatment groups on each of these subsets. Univariate
analysis of variance (ANOVA) and Tukey's pairwise procedure
were used for group comparisons of the 35 variables. The
MANOVA and ANOVA were also used to assess the effects of
age at diagnosis.
Results

Although group I did not differ significantly from group II on as
many measures as did group 111, there were consistent trends in
this direction (Figures 1, 2, and 3); thus, the pattern of differences
between the CNS-irradiated group and each of the nonirradiated
groups is essentially the same.
Statistical analyses determined that the irradiated group generally performed significantly lower than the nonirradiated groups
on nonlanguage subsets. These subsets and the specific tests
within the subsets accounting for the differences in scores are as
follows: FSIQ (P < .003) (a combination of VIQ & PIQ scores);
VIQ (P < .005), arithmetic subset of the Wechsler VIQ test
(comprised of verbal, visual-spatial, and visual-motor [arithmetic]
tests); PIO (P < .001 ), block design and coding subtests of the
Wechsler PIQ Test; academic achievement (P < .032), the Wide
Range Achievement Test's written spelling and arithmetic subtests; visual-motor skills (P < .024), the Beery Visual-Motor
Integration Test; motor skills (P < .017), the Halstead-Reitan
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GROUP I (CNS medication)
GROUP II (CNS medication + XRT)

e- -•

GROUP Ill (No CNS treatment)

.___

+1 S.D.

M

____ ..... ___

.

- 1 S.D.
FSIQ

VIQ
IQ TESTS

PIO

SP

AR

RR

RC

ACADEMIC ACHIEVEMENT TESTS

Fig. 1. Performance of three treatment groups on IQ and
academic achievement tests. All test performances are expressed in standard scores with a mean of 100 and a standard
deviation of 15. Abbreviations are as follows: FSIQ = full-scale
IQ; VIQ = verbal IQ; PIQ = performance IQ; SP = spelling; AR
= arithmetic; RR = reading recognition; RC = reading comprehension.

finger-tapping and trailmaking tasks and the Grooved Pegboard
Test; memory (P < .023), the Nonverbal Selective Reminding
Test (spatial memory) (Table 1). Significant differences were not
found on the language or tactile-spatial subsets.
On those tests designed to measure verbal functioning alone,
the irradiated group generally performed at a level more comparable to the other two groups (e.g . the information and comprehension IQ subtests of the Wechsler IQ test [Figure 2]; the
Verbal Selective Reminding Test [verbal memory] and Word
Fluency Test [Figure 3]; the Wide Range Achievement Test's
reading subtest [Figure 1]; and the Peabody Picture Vocabulary
Test [Figure 3]) .
To assess the relative effects of age at diagnosis on the
neuropsychologic test results, the study popu lation was divided
into two age groups:< 60 months at diagnosis (44 patients) and
> 60 months at diagnosis (30 patients). This grouping was based
on the rationale that a period of rapid growth in cognitive skills
occurs between the ages of 5 and 7 years. In both age groups,
there were similar proportions of irradiated and nonirradiated
children.
Significant differences in age-based mean scores between the
two age groups occurred for four subsets: academic achievement
(P < .013), visual-motor skills (P < .023), memory (spatial) (P <
.021 ), and motor skills (P < .052). Poorer performance on these
four subsets was associated with earlier diagnosis, except for
performance on academic achievement. The children diagnosed
earlier had higher reading achievement scores. It is likely that
children in the older group were in treatment and missed school
when reading was being taught. The majority of younger children
had completed treatment for cancer before starting school. The
above findings for the effects of age at diagnosis were present in
all treatment groups. Irradiated children were no more affected by
age at diagnosis than were children in the nonirradiated groups.
These results show that the effects of treatment do not depend
on the age of the child. Radiation was found to have a detrimental
effect on neuropsychologic functioning regardless of age at
diagnosis. Children irradiated at an earlier age consistently
scored lower than those in the nonirradiated groups on the same
subsets as did children irradiated at a later age (IQ, academic
achievement, memory [spatial], and motor skills). Also, IQ scores
were similarly low for irradiated children of both age groups.
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Other studies have suggested that CNS prophylaxis impairs
the cognitive functioning of long-term survivors of childhood
leukemia and lymphoma. However, these studies have yielded a
variety of conflicting results in terms of the type of treatment
necessary to produce these effects and the nature and extent of
post-treatment cognitive difficulties. Our study, because of (1) the
number of patients evaluated, (2) use of a control group, (3)
comprehensiveness and consistency of neuropsychologic testing
instruments utilized, (4) rigorous statistical techniques utilized, (5)
comparability across groups for sex, age at diagnosis, and
ethnicity, and (6) constancy of institution and examiner, helps
clarify results of previous studies pertaining to the long-term
effects of CNS prophylaxis.
Results of our study are similar to those of Rowland et al.,* who
reported the use of an extensive neuropsychologic test battery on
large numbers of childhood cancer patients. Rowland et al.
compared three groups of survivors of acute lymphocytic
leukemia. In that study, a group of CNS-irradiated children, who
also received IT methotrexate (MTX) , scored significantly lower
on IQ and school achievement tests than two other groups of
children receiving MTX alone without CNS irradiation (IT-MTX
and IT-MTX + IV-MTX). Because many of these children were
evaluated only 1 year after CNS prophylaxis, the investigators
were uncertain about the stability of the group differences over
time. Our results help clarify that issue; the mean number of
years from diagnosis to evaluation for CNS impairment for our
leukemia and lymphoma groups was 7 to 8 years, and for the
control group, 10 years. Together, these two studies imply that
the effects of radiation on the neuropsychologic functioning of
childhood cancer patients do not change over time. These effects
seem to appear shortly after treatment (1 to 3 years) and remain
in long-term survivors.
*Rowland J, Glidewell 0 , and Sibley R. 1982. Effect of cranial radiation (CRT) on
neuropsychologic function in children with acute lymphocy1ic leukemia (abstract). Proc
Am Soc Clin Oncol 1 :123.
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Fig. 2. Performance of three treatment groups on IQ subtests
and visual-motor, motor, and spatial-memory tests. All test
performances are expressed in standard scores with a mean of
10 and a standard deviation of 3. Abbreviations are as follows:
INF = information; SIM = similarities; AR = arithmetic; COM =
comprehension; OS = digit span; PC = picture completion; BO
= block design; OA = object assembly; COD = coding; VMI =
visual-motor integration; RD = recognition discrimination; LTS
= long-term storage; CR = continuous retrieval; FT = finger
tapping; TA = trailmaking A; TB = trailmaking B; GP =
grooved pegboard; DH = dominant hand; NOH = nondominant
hand.
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Fig. 3. Performance of three treatment groups on language,
verbal memory, and stereognosis. All test performances are
expressed in standard scores with a mean of 1O and a standard
deviation of 3. Abbreviations are as follows: PPVT = Peabody
Picture Vocabulary Test; RAN = rapid naming; WF = word
fluency; L TS = long-term storage; CR = continuous retrieval;
ST-DC = stereognosis, dominant hand, correct response; STDT = stereognosis, dominant hand, timed test; ST-NOC =
stereognosis, nondominant hand, correct response; ST-NDT =
stereognosis, nondominant hand, timed test.

Whether the effects of CNS irradiation on cognitive skills are
diffuse or specific is a question of concern. Although there was a
general lowering of scores across all variables for the irradiated
group (results often interpreted as indicative of diffuse CNS
impairment), differences between the irradiated and nonirradiated groups were significant only for nonlanguage skills often
associated with problems in arithmetic. Impairment of nonlanguage skills only in irradiated patients is particularly evident on
the memory tasks, which employ completely analogous tests for
measuring memory skills, differing only in the types of material to
be remembered (verbal or visual-spatial) (Figures 2 and 3).
Group II scored significantly lower than groups I and Ill on the
visual-spatial test only. Such results indicate that the irradiated
group most likely had specific rather than diffuse impairment.
The finding that the irradiated group was no more affected by
age at diagnosis than the other two treatment groups questions
the hypothesis that cognitive functions are more affected by
radiation in younger children. Our results show that CNS irradiation is associated with poorer performance regardless of age at
diagnosis.
Because the two CNS-treated groups (groups I and II) received
similar chemotherapy and had equal opportunity for school
attendance, CNS irradiation (or possibly CNS irradiation combined with IT chemotherapy) appears to be the primary cause of
abnormalities in the neuropsychologic functioning of group II
children. This conclusion is supported by the lack of difference
between scores of the nonirradiated groups I and Ill.
These findings suggest that in the absence of irradiation, CNS
treatment does not have a measurable effect on the neuropsychologic functioning of children. Results of this investigation
should support the trend to employ chemotherapy alone for
children with cancers, such as leukemia and lymphoma, that
require CNS prophylaxis.
(Physicians desiring additional information should write or call
Donna R. Copeland, PhD, Department of Pediatrics, MDAH Box
215, The University of Texas M. D. Anderson Hospital and Tumor
Institute at Houston, 6723 Bertner Avenue, Houston, Texas
77030 (713) 792-6620. -ED)
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Metastasis
Conunued "om page 1
right "seed" and the right "soil" to produce a metastasis. Paget
said almost 100 years ago that in this biologic process we must
consider the tumor cell properties and host factors, which
together determine the outcome of the interaction. What I've
been saying is simply a reinvention of Paget' s "seed and soil"
hypothesis. A tumor with some cells better able to metastasize
than others exhibits diversity, not uniformity. The scientific term
for diversity is heterogeneity.

Was Paget's theory widely accepted, or forgotten?
The idea was debated and discarded. A more popular hypothesis originated in the middle 1920s: that metastasis occurs most
frequently in the lungs and the liver because of hemodynamics.
Tumor cells of abdominal tumors were thought to travel through
the circulation to the capillary bed of the liver. Tumor cells of
tumors growing on the body's periphery, the breast or skin for
example, were thought to metastasize to the lung by way of the
venous circulation where the blood drains first to the heart and
then to the lung.
Very detailed experiments have been performed in mice to test
this hypothesis. In one such experiment in our laboratory, a small
fragment of lung of a mouse was embedded in a muscle of one
leg, and a small fragment of kidney was implanted in the other leg
as a control. The mouse was then injected with melanoma cells
exhibiting preferential growth in the lung. If the tumor were to
metastasize to the lung because its capillary bed was first
encountered by the tumor cells, then metastasis would occur only
in the natural lung, but not in the lung fragment implanted in the
leg muscle. If metastasis were to occur as a consequence of
interaction between the tumor, "the seed," and the organ, "the
soil," metastasis would grow in the natural lung and in the
implanted lung fragment in the leg, but not in the implanted
kidney in the other leg. And that's exactly what happened. The
melanoma proliferated in the natural lung (the in situ lung) and in
the implanted lung fragment, but not in the implanted kidney.
Most researchers today agree that metastasis is not a chance
event and that tumor cells are indeed heterogeneous for metastatic properties.
Why have we not been able to control metastasis? Is It
because of tumor heterogeneity?
Partially. The primary reason is that in the majority of patients,
except those with skin cancer, by the time of diagnosis, metastasis has already occurred. If there are already tumor colonies in
the liver, for example, removing the primary tumor has little effect
on the proliferating cells in the liver. Also, because the metastasis
may be comprised of cells different than those in the primary
tumor, the metastasis may be unresponsive to drug therapy
designed for the primary tumor. In addition, cells in one metastasis may be distinctly different from cells in another metastasis.
This fact is often evident clinically. If a patient presents with
multiple metastases, sometimes several metastases regress
while one progresses during chemotherapy.
Why have you chosen macrophages to help combat metastatic cancer, rather than T cells, natural-killer cells, or any
other defense cell?

6

Because the major dilemma for the treatment of metastasis is
that metastatic tumor cells are biologically very diverse. I was
therefore intrigued by the observations, made many years ago in
my own lab and others, that activated macrophages harvested
from animals with infection can kill tumor cells, but not normal
cells. Moreover, activated macrophages in culture kill tumor cells
whether or not these cells are sensitive or resistant to lymphocytes or natural-killer cells or sensitive or resistant to drugs. T
cells kill tumor cells, but we can select for tumor cells resistant to
T cells. We can select for cells resistant to natural-killer cells. But
no one has been able to select for cells resistant to macrophages.
I'm not talking about increased sensitivity or decreased sensitivity
to macrophages. I'm talking about absolute resistance . We have
not detected it, nor has anyone else.
So we realized the following : The major dilemma in cancer
treatment is to eliminate those cells that conventional treatment
cannot eliminate. With a 1-cm tumor, or approximately 1 x 109
cells, the destruction of 99.9% leaves 1 x 106 cells to proliferate.
These are the fatal tumor cells. Therefore, the challenge to the
basic researcher interested in therapy is not to design more and
more drugs that can eliminate the 99.9% of tumor cells. The
challenge is to design an approach that will destroy the remaining
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Activated human blood macrophages lyse a human melanoma.
Macrophages were activated with liposome-encapsulated
muramyl dipeptide. (This scanning electron micrograph of
activated macrophages, produced in Dr Fidler's Laboratory at
the National Cancer lnstitute's Frederick Cancer Research
Facility, was provided by Dr Corazon Bucana.)

A human blood macrophage lyses a human melanoma cell
(matrix in bottom third of photograph). The macrophage was
activated by phagocytosing liposome-encapsulated muramyl
dipeptide (vesicle in upper left corner). (This electron micrograph of an activated macrophage was also provided by Dr
Corazon Bucana.)

small number of fatal cells. We believe that macrophages can
accomplish this task.

are the results obtained by packaging in the same liposome two
different signals, such as MDP and lymphokines; synergism
occurs. Superior results in macrophage activation and treatment
of metastasis are achieved when each liposome contains two
diverse activation signals, as compared to results achieved with a
single liposome-encapsulated substance.

Must macrophages be activated to be effective against
tumor cells? If so, what method do you use?
Yes, macrophages normally operate in the body at low levels
and must be activated to lyse tumor cells. In vivo, there are two
major ways in which macrophages are activated: by interaction of
macrophages with micro-organisms, such as bacteria and its
products, and b_
y interaction with lymphokines.
The first method of activation occurs in every multicellular
animal. Macrophages in the horseshoe crab, a living fossil,
exhibit panic reactions to endotoxins in the same manner as
human macrophages. Macrophages are also activated in vivo by
lymphokines, soluble mediators released by T cells when stimulated by an antigen.
It is very difficult to activate macrophages in vivo by systemic
injection of lymphokines or a bacterial product because of the
side effects. To deliver these activating agents to macrophages,
we use synthetic membranes called liposomes or lipid vesicles
made of phospholipids, basic components of every cell membrane in the body. By shaking these synthetic membranes in a
test tube we create a multilaminal, multilayered ball that, when
cut crosswise, looks like an onion. The liposome is used to carry
the activating substance, which remains trapped between the
membrane layers.
The liposomes are injected into animals intravenously. Why? A
major role of macrophages in the body is to clear dead cells, dead
bacteria, and foreign particles from the bloodstream. Liposomes
injected intravenously are phagocytosed by macrophages; if the
liposomes contain activation signals (a bacterial product or
lymphokines), the macrophages then respond to these stimuli.
The bacterial product we use is muramyl dipeptide (MDP), a
synthetic molecule identified as the basic unit in a bacterial cell
wall that leads to immune potentiation. Experiments with other
liposome-encapsulated substances are ongoing. Most interesting
Vol. 29, No. 1
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How have you tested the effectiveness of macrophage
activation In controlling metastasis? What were the results?
The routine experiment has been to inject mice intradermally
with melanoma cells and allow lung and lymph node metastases
to develop. After the primary tumors are surgically removed, the
mice are treated by repeated injections (2 injections a week for 4
weeks) of liposomes that contain an immunomodulator or a
combination of substances; control mice are treated with liposomes that contain placebos. The survival of the mice is then
recorded. In our laboratory, control mice died within 90 days after
the experiment began. Of those mice receiving macrophage
therapy, 60 to 70% survived until the experiment was terminated
(approximately 1 year after it began). Survival was associated
with measurable regression of metastases. Other researchers
have had similar results.
How do you know such results occur from macrophage
activation rather than from the activity of other defense
cells?
Several experiments indicate that macrophage activation produces these results. First, if we depress the macrophage system
in a mouse, liposome treatment fails. Second, we can harvest
macrophages that are very cytotoxic from regressing tumors.
These results indicate that macrophages are central or essential
cells. Mind you, I'm not saying that macrophages are the only
active cells; they may indeed recruit other cells. However, we
have obtained therapeutic results using our method in nude mice,
which are totally deficient in T cells, and in mice whose naturalkiller cells have been depleted.
Continued on page 8
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Metastasis .
Continued from page 7

How will your method be used most effectively In the
treatment of cancer patients?
A multifactorial disease such as cancer must be treated by
multiple approaches. Tumor cell destruction by macrophages is
very limited. Macrophages first must find tumor cells and then
form direct contact with them. In a mouse, we estimate that
macrophages can kill approximately 1 to 5 x 106 cells and no
mace. This is a very small number of tumor cells.
To overcome this limitation, we are investigating a number of
multimodal approaches. The first is to use macrophage activation
after the bulk tumor has been removed by surgery or after
radiotherapy. The second approach is to use macrophage
activation in combination with chemotherapy.
Chemotherapy used alone is limited by host toxicity. When
chemotherapy is used with macrophage therapy a smaller drug
dose is required, thus alleviating the problem of host toxicity.
Toxicity can then be defined as the quantity of the drug that will
interfere with macrophage activation. For Adriamycin, for example, we have found that dose to be approximately 2.5 mg/kg of
body weight in mice. We have given this dose in mice (the usual
dose is 13 to 15 mg/kg) and then a week later have activated
macrophages with liposome-encapsulated substances. The logic
is that if we administer a small drug dose to reduce the tumor
burden from 109 to just 106 cells, for example, macrophages can
then be activated to destroy what remains. We give optimal
chemotherapy and maximal macrophage activation. Thus, both
modalities are used for maximal benefit.
When do you think we will start using these methods In
patients?
I don't know. Toxicity studies are required. Macrophage
activation is not toxic in mice and guinea pigs, and that's
encouraging. These results, however, cannot be immediately
translated to humans. Muramyl dipeptide toxicity studies have
never been carried out in humans.
Why have you come to UT MDAH? What do you hope to
accomplish?
My work at UT MDAH will allow me to test in clinical situations
many hypotheses developed in mice and in experimental animals. The interaction between us and our clinical colleagues at
UT MDAH has been outstanding.
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H you do see this method used successfully In humans, what
areas do you hope to explore next?
Our research continually raises other questions. We know a
great deal about how metastasis occurs. We don 't know why it
happens. All things in nature occur for a reason. I would like to
understand the reason cancers metastasize.
(Physicians desiring additional information should write Isaiah

J. Fidler, Department of Cell Biology, MDAH Box 173, The
University of Texas M. D. Anderson Hospital and Tumor Institute
at Houston, 6723 Bertner Avenue, Houston, Texas 77030.-ED)
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